⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Myasthenia Gravis Registry in China

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Myasthenia Gravis Registry in China

Official Title: Myasthenia Gravis Registry in China

Study ID: NCT06241521

Interventions

Study Description

Brief Summary: Myasthenia gravis (MG) is an autoimmune disease caused by dysfunction at the neuromuscular junction, characterized by partial or generalized skeletal muscle weakness and fatigability. The estimated annual incidence rate of MG in China is 0.68/100,000, with a high rate of relapse and poor treatment compliance. This study is a prospective, observational, multi-center patient registry across China. To support standardized management and follow-up of MG patients in China, a Cloud-based MG Patient Management Platform (CN MG Base) was established in September 2023 with the support of the Chinese Rare Diseases Alliance. The platform aims to collect longitudinal clinical data including demographic information, age of onset, medical history, comorbidities, medication usage, treatment responses, and others. It is intended to collect newly registered MG cases each year and follow up with these patients at one-year intervals for ten years

Detailed Description: This study is a observational nationwide multicenter MG registry research. Starting from the baseline, annual follow-ups will be conducted to prospectively collect information on treatment medications, prognosis, and safety events. The following classification definitions can be applied: ① MG clinical subtypes (ocular, early-onset generalized, thymoma-related, late-onset generalized, MuSK-related, and seronegative); ② Different treatment methods (classic immunotherapy group, B-cell-targeted therapy, complement inhibition therapy, rapid-acting therapy, and IL-6 pathway inhibitors, etc.).

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Beijing Hospital, Beijing, Beijing, China

Xuanwu hospital, Capital medical university, Beijing, Beijing, China

Peking Union Medical College Hospital, Beijing, Beijing, China

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

The Third Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Xiangya hospital, Central south university, Changsha, Hunan, China

The First Hospital, Soochow University, Suzhou, Jiangsu, China

Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

The First Hospital, Jilin University, Changchun, Jilin, China

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Tangdu Hospital, The Air Force Medical University, Xi'an, Shanxi, China

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: